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Abstract
Autoimmunity and inﬂammation are associated with marked changes in lipid and lipoprotein metabolism in SLE.
Autoantibodies and cytokines are able to modulate lipoprotein lipase (LPL) activity, a key enzyme in lipid metabolism, with
a consequent “lupus pattern” of dyslipoproteinemia characterized by elevated levels of very low-density lipoprotein
cholesterol (VLDL) and triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL) levels. This pattern favors
an enhanced LDL oxidation with a subsequent deleterious foam cell formation. Autoantibodies and immunocomplexes may
aggravate this oxidative injury by inducing accumulation and deposition of oxLDL in endothelial cells. Drugs and associated
diseases usually magnify the close interaction of these factors and further promote the proatherogenic environment of
this disease.
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Introduction
Atherosclerosis has been increasingly recognized as
an important cause of morbidity and mortality in
systemic lupus erythematosus (SLE) (Hahn 2003;
Bruce 2005; Frostegard 2005; Shoenfeld et al. 2005)
and therefore, understanding the pathogenesis of this
process seems important to givelupus patients a better
long-term outcome and quality of life. Indeed, these
patients are known to have an increased frequency of
traditional risk factors such as hypertension, dyslipi-
demia, obesity and diabetes mellitus (Petri et al. 1992;
Bruce et al. 1999; Svenungsson et al. 2001; Bruce
2005). However, it has now become clear that
atherosclerosis cannot be entirely explained by
Framingham risk factors and may be associated with
a combination of both traditional and nontraditional
risk factors (Esdaile et al. 2001; Svenungsson et al.
2001; Lee et al. 2006).
Interestingly, immune and inﬂammatory mecha-
nisms seem to have a role in the pathogenesis of
atherosclerotic vascular damage (Ross 1993; Ross
1999; Libby 2002). This raises the exciting possibility
that SLE itself may be atherogenic through chronic
activation of the immune system and inﬂammatory
process. In fact, autoantibodies such as antiphos-
pholipid, anti-b2-glycoprotein I, antioxidized low-
density lipoprotein and anti-lipoprotein lipase and
elevated inﬂammatory markers such as C reactive
proteins (CRP) and interleukin 6 (IL-6) are common
ﬁndings of SLE.
It is therefore reasonable to postulate that the
interaction of disease associated factors induces
speciﬁc alterations in lipoprotein metabolism which
is aggravated by drugs and associated conditions
frequently observed in lupus patients.
The “lupus pattern” of dyslipoproteinemia
SLE is alleged as a classic model of a chronic immune
complex-mediated inﬂammatory disease and pro-
bably several conditions detected in this disorder
may enhance atherogenesis. Similarly, atherosclerosis
is now assumed as a chronic process closely related
to inﬂammation, which plays a pivotal role in the
mechanisms of induction and progression of the
atherosclerotic process in vessels (Ross 1993; Ross
1999; Libby 2002). It is well known that the acute-
phase response promotes an altered hepatic synthesis
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the complement system, and in lipoprotein meta-
bolism (Gabay and Kushner 1999). Therefore, it
seems reasonable to accept that inﬂammatory con-
ditions of the disease itself would induce speciﬁc
alterations in the lipid proﬁle.
Reinforcing this possibility, sporadic cases of
hyperlipoproteinemia type I (Glueck et al. 1969a,b;
Pauciullo et al. 1986), and V (Alverson and Chase
1977) preceding SLE have been reported and provide
support for the direct involvement of the disease in
this process. Subsequently, deﬁnitive evidence for
primary abnormalities of lipoprotein metabolism
due to SLE per se was recognized (Ilowite et al.
1988; Borba and Bonfa 1997). The “lupus pattern”
of dyslipoproteinemia identiﬁed was characterized
by elevated levels of very low-density lipoprotein
cholesterol (VLDL) and triglycerides (TG), and
lower high-density lipoprotein cholesterol (HDL)
levels (Ilowite et al. 1988; Borba and Bonfa 1997).
Interestingly, activity seems to worsen this dyslipo-
proteinemia since a striking increase of VLDL and
TG levels and decrease of HDL levels were directly
correlated with SLEDAI scores (Borba and Bonfa
1997).
It should be emphasized that the most common
abnormality in SLE is low HDL levels, which are
detected in almost 80% of patients with active
disease but also in approximately one-third of
inactive patients (Borba and Bonfa 1997). Since
HDL, levels are known to be inversely related to
coronary artery disease (CAD) risk (Gordon et al.
1977; Castelli et al. 1986; Jacobs et al. 1990) this
ﬁnding is certainly of concern. Noteworthy, an
increase in triglyceride levels determined low HDL
levels (Deckelbaum et al. 1984; Schaefer et al. 1987)
and hypertriglyceridemia itself is also recognized as
an independent risk factor in women (Castelli 1986;
Castelli 1988; Bass et al. 1993). Together, these data
suggest that SLE itself promotes a proatherogenic
lipid proﬁle.
These abnormalities observed in untreated active
and inactive SLE might be explained by an
accumulation of the main triglyceride-rich lipopro-
teins, namely chylomicrons and VLDL. In their
catabolism, both lipoproteins undergo degradation by
lipoprotein lipase (LPL) which is the enzyme involved
in the lipolysis process (Goldberg 1996). Indeed, a low
LPL activity results in accumulation of not only
chylomicron but also VLDL, leading to high TG and
low HDL levels (Deckelbaum et al. 1984; Schaefer
et al. 1987).
Interestingly, a signiﬁcant impairment of LPL
activity in SLE was observed using an in vitro lipolysis
assay (Borba et al. 2000). Moreover, a striking
reduction of the intravascular lipolysis of chylomicron
by LPL associated with a pronounced delay in
removal of their remnants by liver receptors was also
demonstrated in SLE patients (Borba et al. 2000).
Furthermore, the recent description of high frequency
of antibodies to lipoprotein lipase (anti-LPL) in SLE
raises the possibility that these autoantibodies may
modulate LPL activity in SLE (Reichlin et al. 2002;
de Carvalho et al. 2004) as has been described
for autoimmune hyperlipidemia (Beaumont and
Beaumont 1977).
Remarkably, the presence of these autoantibodies
was not only signiﬁcantly associated with increased
triglyceride levels (Reichlin et al. 2002; de Carvalho
et al. 2004) but also with disease activity (SLEDAI),
ESR and CRP (de Carvalho et al. 2004), suggesting
thatimmunemechanismandinﬂammatoryprocessare
concomitantly involved in SLE dyslipoproteinemia.
Cytokines and lupus dyslipoproteinemia
The possible role of inﬂammation in modulating LPL
enzyme is emphasized by the recent description of a
signiﬁcant down-regulation of LPL activity induced
by TNF, IL-1 and IFN-gamma (Enholm et al. 1982;
Beutler and Cerami 1985; Semb et al. 1987). An
enhanced production of these cytokines is a charac-
teristic of SLE, particularly during active disease
(Hooks et al. 1982; Tanaka et al. 1988; Maury and
Teppo 1989; Spronk et al. 1992).
In this regard, it is known that tumor necrosis factor
(TNF) promotes a prompt increase in circulating
TG when administered to humans (Feinberg et al.
1988) which is due to an increase hepatic synthesis
of VLDL. Moreover, TNF have the ability to inhibit
LPL (Beutler et al. 1985). It was recently described
that levels of circulating TNF are raised in SLE
and correlate with active disease and TG levels
(Svenungsson et al. 2003a,b). In addition, TNF
activity was closely associated with elevated TGs
among SLE patients with previous cardiovascular
disease (Svenungsson et al. 2003a). Interestingly,
HDL-associated apolipoprotein A-I has been shown
to decrease TNF production through its inhibition of
contact-mediated activation of monocytes by binding
to stimulated T cells (Hyka et al. 2001). In this regard,
low HDL levels seem to be not only a consequence of
active disease but may also indirectly contribute to
enhance inﬂammation in SLE.
Additionally, in SLE the altered lipid proﬁle may
be inﬂuenced by high concentrations of two other
proatherogenic cytokines: monocyte chemoattractant
protein-1 (MCP-1) and IL-6 (Asanuma et al. 2006).
In fact, MCP-1 concentrations are related with
monocyte inﬁltration in atherosclerotic lesions and
are associated with atherosclerosis in the general
population. Moreover, it has been demonstrated that
anti-MCP-1 gene therapy limited progression and
destabilization of atherosclerosis in animal models
(Reckless et al. 1999; Inoue et al. 2002). Interestingly,
higher MCP-1 levels were detected in SLE and were
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increased TG levels (Asanuma et al. 2006). Further-
more, high IL-6 concentrations were associated with
low HDL levels (Asanuma et al. 2006) in the same
study reinforcing the relevance of cytokines in the lipid
proﬁle of SLE patients.
Accordingly, TNF-alpha and interleukins-1 and 6
are known to stimulate the CRP synthesis by the liver
(Gabay and Kushner 1999). The additional obser-
vation that these cytokines can affect LPL function
(Beutler and Cerami 1985; Semb et al. 1987) further
supports their role in lupus dyslipoproteinemia. CRP
levels are also increased in the metabolic syndrome
(Festa et al. 2000; Tamakoshi et al. 2003; Aronson
et al. 2004), hypertriglyceridemia (Grau et al. 1996;
Tamakoshi et al. 2003; Fredrikson et al. 2004; Jialal
et al. 2004) and in patients with low levels of HDL
cholesterol (Tamakoshi et al. 2003; Fredrikson et al.
2004; Jialal et al. 2004).
Other autoantibodies and lupus
dyslipoproteinemia
It has been extensively demonstrated that hypertrigly-
ceridemia enhances replacement of cholesterol esters
in the core of LDL particles, creating small dense
LDL (Richards et al. 1989) which are easily ﬁltered
into the arterial wall (Stender and Zilversmit 1981)
and more susceptible to oxidation (Chait et al. 1993).
Oxidized LDL (oxLDL) may lead to the formation of
antigenic neoepitopes that bind to scavenger receptors
of macrophages, enhancing oxLDL uptake with
subsequent foam cell formation (Heinecke 1997).
On the other hand, HDL has an antiatherogenic effect
by inhibiting LDL oxidation (Parthasarathy et al.
1990), reducing LDL lipid hydroperoxides (Van
Lenten et al. 1995) and oxidized phospholipids
(Navab et al. 2004), and transporting oxidized lipids
to the liver in the reverse cholesterol transport (Fluiter
et al. 1996).
Therefore, the “lupus pattern” of dyslipoproteine-
mia characterized by hypertriglyceridemia and low
HDL should certainly contribute for an enhanced
LDL oxidation (oxLDL). Indeed, high levels of
oxLDL (i.e. Apo B lipoproteins containing oxPL)
were recently identiﬁed in this disease (Frostegard
et al. 2005). Furthermore, antibodies to oxLDL
epitopes were described in SLE (Vaarala et al. 1993;
George et al. 1999; Wu et al. 1999; Frostegard et al.
2005). It also seems possible that these antibodies
would enhance the accumulation of oxidized LDL to
the endothelial wall by increasing LDL uptake via
Fc-receptor, as ﬁrst hypothesized by Vaarala et al.
(1993). Of interest, a possible crossreaction between
anti-oxLDL and cardiolipin antibodies was also
reported in SLE (Vaarala et al. 1993; George et al.
1999; Wu et al. 1999; Frostegard et al. 2005), as well
as a cross-reactivity between aCL, anti-HDL and
anti-apoA1 IgG antibodies (Delgado et al. 2003).
These ﬁndings may explain in part the association of
IgG anticardiopilin (aCL) with low HDL and low
apolipoprotein A-1 (apoA1) levels in these patients
(Lahita et al. 1993). Intriguingly, high levels of anti-
apoA1 antibodies were associated to low HDL levels
in SLE (Dinu et al. 1998a,b) and further studies
are needed to clarify its participation in the HDL
metabolism.
High serum levels of oxLDL/b2GPI complexes and
IgG antibodies to these complexes were also detected
in SLE (Kobayashi et al. 2001, 2003; Lopez et al.
2005, 2006). These atherogenic complexes are
formed mainly in the atherosclerotic lesions and thus
indicate a widespread underlying oxidative injury
(Lopez et al. 2006). b2GPI seems to bind to oxLDLto
counteract its inﬂammatory effect (oxidative) and to
promote macrophage uptake via scavenger but the
large complexes are usually deposited and promote
foam cells formation. In addition, the presence of anti-
b2GPI antibodies enhances in vitro macrophage
uptake of these complexes (Kobayashi et al. 2001).
Interestingly, oxLDL/b2GPI complexes and IgG
anti-/b2GPI antibodies were detected in lupus
patients that had high TG and low HDL levels
(Lopez et al. 2006).
Drugs in lupus dyslipoproteinemia
Several drugs commonly used in the treatment of SLE
also induce undesirable effects on lipids but corticos-
teroids are always remembered since their alterations
were extensively studied in SLE (Ettinger et al. 1987;
Ettinger and Hazzard 1988; Ilowite et al. 1988;
MacGregor et al. 1992; Leong et al. 1994; Petri et al.
1994; Bruce et al. 1999).
In fact, chronic corticosteroids use in SLE is
associated to increase total plasma cholesterol and
its fractions (LDL and HDL) levels, and also TG
(Ettinger et al. 1987; Ettinger and Hazzard 1988;
Ilowiteetal.1988;MacGregoretal.1992;Leong etal.
1994; Petri et al. 1994; Bruce et al. 1999), which seem
mediated by increased plasma insulin levels and lipid
production by the liver, and impaired lipid catabolism
(Sholter and Armstrong 2000). This effect could be
identiﬁed after a short period of 1–2 months of this
therapy (Ilowite et al. 1988) and is also dose related
since low prednisone daily doses do not signiﬁcantly
alter the lipid proﬁle (MacGregor et al. 1992; Petri
et al. 1994). In fact, Petri et al showed that for
each 10mg increase in prednisone dosage, there is a
7.5mg% corresponding increase in serum cholesterol
and a 1.1mmHg increase in mean arterial pressure
(Petri et al. 1994). In addition, corticosteroids can also
indirectly promote other traditional risk factors such
as obesity, systemic hypertension, glucose intolerance
and diabetes (Petri et al. 1992). Interestingly, Manzi
et al found that corticosteroid use was associated with
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atherosclerosis in SLE patients, independent of the
development or worsening of hypertension and
diabetes (Manzi et al. 1999).
On the other hand, a possible antihyperlipidemic
property of antimalarials in SLE was ﬁrst demon-
strated in a combined group of patients with
rheumatoid arthritis and SLE treated with hydroxy-
chloroquine (Wallace et al. 1990). Subsequently, Petri
et al found that the use of hydroxychloroquine was
associated with an 8.5% decrease in serum cholesterol
(Petri et al. 1994). Thereafter, studies that speciﬁcally
addressed its effect on lipoproteins in lupus patients
had conﬁrmed the beneﬁcial effect on lipids (Hodis
et al. 1993; Kavanaugh et al. 1997; Rahman et al.
1999; Borba and Bonfa 2001). Interestingly, a
signiﬁcant increase in HDL levels is observed in SLE
patients taking antimalarials with or without pre-
dnisone (Borba and Bonfa 2001). Moreover, a
beneﬁcial effect in the diabetes control has been
suggested in randomized trials after the use of
hydroxychloroquine probably by the alteration of
insulin resistance (Powrie et al. 1993; Gerstein et al.
2002).
Importantly, several other drugs such as anti-
convulsants, antihypertensives (beta blockers and
diuretics), estrogen and/or progesterone containing
agents should also be considered since they can
promote speciﬁc alterations on the lipid proﬁle
(Henkin et al. 1992).
Associated diseases in lupus dyslipoproteinemia
Renal involvement, such as uremia and nephrotic
syndrome,is frequentlyobservedinthe course of SLE,
andthesesconditionsareknowntoalterthelipidproﬁle
(Appel et al. 1985; Attman and Alaupovic 1991). Also
to be considered is the concurrence of other systemic
disorderssuchasthyroiddiseaseanddiabetesmellitus,
which promote distinct changes in lipoprotein metab-
olism (Thompson etal. 1981; Brown 1994). Addition-
ally, as patients live longer, lipid abnormalities due to
increasing age (Heiss et al. 1980) and menopause
(Kannel et al. 1976) may become relevant.
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